p90RSK Kinase: Recombinant Rabbit Monoclonal Antibody Tools for Probing Multidimensional Kinase‑Signalling Regulation
p90RSK as a Central Downstream Effector within the Ras‑MAPK Signalling Cascade
p90RSK belongs to the AGC‑family serine‑threonine kinase group and represents a key effector molecule operating downstream of Ras‑MAPK‑ERK signalling cascades. This kinase carries two functionally distinct kinase domains within one polypeptide chain. The N‑terminal domain executes substrate phosphorylation events, while the C‑terminal domain participates in intramolecular autoregulatory activation processes.
p90RSK phosphorylates a broad collection of downstream substrates including transcription factors, ribosomal proteins, cell‑cycle mediators and epigenetic‑modification enzymes. These substrate‑targeting events govern core cellular outputs such as proliferation, survival, differentiation and metabolic reprogramming in cell‑culture experimental systems. Dysregulated p90RSK signalling correlates with tumour progression and acquired drug‑resistance phenotypes across multiple cancer‑model systems.
High‑quality antibody tools are required to distinguish total p90RSK protein pools from phosphorylated activated fractions and trace isoform‑specific dynamics. Recombinant rabbit‑monoclonal‑antibody formats benefit from broad epitope‑recognition capacity and high intrinsic affinity, enabling detection of conformational and post‑translation‑modified epitopes for signalling‑network investigation.
Key Structural Considerations for Designing Recombinant Anti‑p90RSK Antibodies
The p90RSK polypeptide is organized into N‑terminal kinase domain, central linker segment and C‑terminal kinase domain. Full kinase activation depends on ERK‑driven phosphorylation events at residues including Thr359 and Ser389 alongside inter‑domain intramolecular interactions. Antibody development projects must define intended detection targets: total‑protein or phospho‑modified activated epitopes.
Antibodies for total‑protein detection usually target conserved polypeptide stretches and suit western‑blot profiling and immunoprecipitation workflows. Phospho‑specific antibody clones require precise recognition of phosphorylation‑modified residues that mediate kinase activation. Multiple alternative‑splice variants and diverse post‑translational modifications further increase molecular heterogeneity of endogenous p90RSK samples.
Recombinant protein fragments or synthetic peptides serve as immunogens to cover distinct structural domains and modified motifs for diverse clone enrichment. Rabbit immune repertoires can generate high‑affinity clones recognizing conformation‑dependent and modification‑sensitive epitopes. For FFPE‑immunohistochemistry workflows, candidate clones need stable epitope performance after formalin cross‑linking treatment.
Experimental Applications of Anti‑p90RSK Antibodies in Signal‑Transduction Research
p90RSK activation status serves as a measurable readout reflecting upstream ERK signal intensity and negative‑feedback regulatory responses within stimulated cell models. Western‑blot workflows using anti‑p90RSK antibodies quantify relative abundance of total kinase alongside phosphorylated activated fractions across different stimulation time courses. These datasets support inference of upstream ERK activation patterns and feedback‑loop dynamics.
Immunofluorescence imaging visualizes nucleocytoplasmic shuttling events of p90RSK within intact cells. Under resting conditions, p90RSK mainly localizes to cytoplasmic compartments; upon stimulation, activated kinase fractions translocate into nuclear regions to phosphorylate transcription factors such as CREB and c‑Fos. Phospho‑specific antibody reagents deliver spatial evidence for activated‑kinase subcellular‑distribution patterns.
Combined immunoprecipitation and in‑vitro kinase‑activity assays enable enrichment of endogenous p90RSK‑containing protein complexes. Researchers can further characterize substrate‑phosphorylation capacity of pulled‑down kinase assemblies under different experimental treatment conditions. These multi‑modal assays support mechanistic dissection of MAPK‑pathway signal‑propagation circuits.
Research Value of p90RSK Antibodies in Disease‑Model and Pre‑Clinical Drug‑Discovery Workflows
Aberrant p90RSK signalling activity has been documented in multiple tumour‑derived experimental systems. Within breast‑cancer‑relevant models, p90RSK modulates oestrogen‑receptor phosphorylation and cell‑cycle‑protein expression, contributing to hormone‑therapy‑resistance phenotypes. Immunohistochemical staining with anti‑p90RSK reagents permits correlation analysis between kinase expression‑activation status and pathological parameters in tumour‑tissue specimen sets.
In lung‑cancer laboratory investigations, p90RSK activity connects with EGFR mutation backgrounds and TKI‑acquired‑resistance readouts. Antibody‑based detection approaches track shifting p90RSK activation levels in drug‑resistant cell lines and help map rewired downstream signalling networks. For neuroscience‑oriented projects, tissue‑section staining reveals p90RSK distribution across brain regions and neuronal subsets for synaptic‑plasticity and neuronal‑survival mechanistic studies.
For inhibitor‑development pipelines, anti‑p90RSK recombinant antibodies support phospho‑ELISA assay construction to quantify target‑kinase suppression after compound exposure. Cell‑based phenotypic assays link p90RSK target‑engagement measurements to cellular‑proliferation‑related readouts. Immunohistochemical profiling of treated tumour tissues evaluates inhibitor‑mediated signal suppression magnitude and duration for in‑vivo pre‑clinical studies. These reagents also support combinatorial‑drug screening by measuring additive signalling‑suppression effects of multi‑compound treatment regimens and tracing compensatory kinase re‑activation in resistant cell populations.
Pan‑Isoform‑Reactive p90RSK Recombinant Rabbit mAb from ANT BIO PTE. LTD.
ANT BIO PTE. LTD. supplies p90RSK Recombinant Rabbit mAb (clone S‑1024‑26, catalog S0B0782). This antibody targets conserved kinase‑domain sequences and recognizes major RSK family isoforms RSK1, RSK2, RSK3 and RSK4 across human, mouse and rat sample materials. It has undergone validation for western blot, immunoprecipitation, immunofluorescence, immunohistochemistry and flow‑cytometry laboratory workflows.
Recombinant antibody manufacturing maintains consistent lot‑to‑lot performance suitable for long‑term serial research projects. Comprehensive supporting documentation includes isoform‑cross‑reactivity data, species‑reactivity profiles and optimized multi‑platform application protocols for end‑user experimental design.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.
